Please login to the form below
Cellectis
This page shows the latest Cellectis news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka
Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka. ... The latest from pharma, biotech and healthcare. Cellectis gains senior scientist from Novartis.
Latest news
-
Sangamo bulks up in cell therapy with TxCell acquisition
Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’favoured TALENS.
-
Gilead signs $3bn-plus gene-editing deal with Sangamo
The deal with Sangamo means rivals in the CAR-T category such asand off-the-shelf specialist Cellectis won’t be able to use the ZFN technology in their own ... Other techniques include CRISPR/Cas9 - used by Novartis and Juno - and Cellectis’favoured
-
Cellectis floored by patient death in CAR-T trial
Cellectis floored by patient death in CAR-T trial. FDA puts two cancer immunotherapy trials on hold. ... It may be that the FDA will exercise greater caution in Cellectis' case.
-
Servier cleared to start US trials CAR-T therapy
The French pharma company entered the race to develop chimeric antigen receptor therapies (CAR-T) for cancer after it acquired exclusive rights to UCART19 from Cellectis in 2015. ... Cellectis specialises in the development of ‘off-the-shelf’CAR-T
-
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial. Investigational New Drug gets go-ahead for trials in patients with two haematological cancers. ... This is not the first time that one of Cellectis' CAR-T candidates has been tested in patients
More from news
Approximately 9 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2015
379. Cellectis. Servier. Option exercise. UCART19, CAR-T allogeneic immunotherapy being tested for chronic lymphocytic leukaemia and acute lymphoblastic leukaemia.
-
Pharma deals in May 2015
Following the collaboration announced in June 2014 with Cellectis, the rumours are now going around that Pfizer may be planning an acquisition with an estimated price tag of $1.6bn.
-
Pharma deals in March 2015
Also Evaluate reports a cautious approach by big pharma. Novartis, J&J and Pfizer (via a deal with Cellectis) are in the go-kart race but other companies such as Merck
-
Pharma deals during June 2014
Cellectis has reserved 12 other targets and Pfizer will provide preclinical development assistance for four of these. ... easily. Cellectis plans to open a research site in the US to work more closely with Pfizer.
-
Deal Watch table for June 2014
350. Medreich/ Meiji Seika. Company acquisition. India-based manufacturing company. 290. Cellectis/ Pfizer.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Zelluna Immunotherapy appoints chief technology officer
Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology.
-
Cellectis’ Mathieu Simon will serve as interim chief medical officer
Cellectis’ Mathieu Simon will serve as interim chief medical officer. He will take over the responsibilities of Loan Hoang-Sayag. ... Cellectis has appointed Mathieu Simon to as interim chief medical officer, taking over the role from Loan Hoan-Sayag,
-
Rainer Boehm and Hervé Hoppenot join Cellectics board
I see exciting opportunities for Cellectis to address unmet medical needs and make a meaningful difference in people’s lives. ... I am excited to be joining the Cellectis board during this important time of growth.”.
-
Dr Niall Murphy and Pierre Schwich join Pharnext
Meanwhile, Pierre Schwich (pictured left) joins Pharnext from Cellectis where he served as chief financial officer from 2011 until 2014. ... Before joining Cellectis, he served as chief financial officer and corporate secretary for Genesys Conferencing,
More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Systematic Review Lead- London
-
Negotiable
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Sudler London - Account Director
-
Competitive
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Sudler London - Senior Medical Writer
-
Competitive
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Associate Scientific Director
-
Salary TBC
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
- New data keeps AbbVie’s star pipeline therapies on track
- Nurturing the growth mindset: The need for ongoing professional development in strategic medical communications
- Superhuman editor wins promotion at Porterhouse Medical
- Innovate UK awards £1m for AI drug discovery project
- Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
- Biotech leaders jump into US free speech debate
PMHub
Wordbird
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
